The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysis
Not Applicable
- Conditions
- hemodialysis patients chronically infected with genotype 1 hepatitis C virus
- Registration Number
- JPRN-UMIN000022563
- Lead Sponsor
- Mitsui Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients who are allergic to paritaprevir, ombitasvir, or ritonavir. 2) patients with decompensated cirrhosis (Child-Pugh Class B or C) 3) pregnant women and women suspected of being pregnant 4) patients ineligible for some other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method antiviral effect (24 weeks after end of administration)
- Secondary Outcome Measures
Name Time Method 1) antiviral effect (4 weeks after end of administration) 2) the improvement of liver function at the end of treatment 3) adverse events